CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
This Document Has Been Replaced By: Prevention and Control of Meningococcal Disease : Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Superseded
This Document Has Been Replaced By: Prevention and Control of Meningococcal Disease : Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease. MMWR 60 (40): 1391-1392.
-
October 14, 2011
-
Source: MMWR. Morbidity and mortality weekly report. 2011; 60(40):1391-2.
Details:
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Corporate Authors:
-
Description:In April 2011, the Food and Drug Administration approved the use of a quadrivalent meningococcal conjugate vaccine (MenACWY-D) (Menactra, Sanofi Pasteur) as a 2-dose primary series among children aged 9 through 23 months (1). Vaccination with meningococcal polysaccharide vaccine (MPSV4) is not recommended for children aged <2 years because of low immunogenicity and short duration of protection in this age group (2). The Advisory Committee on Immunization Practices (ACIP) Meningococcal Vaccine Work Group reviewed data from four clinical studies on the safety and immunogenicity of MenACWY-D in healthy children aged 9 through 23 months. The pivotal immunogenicity study was a Phase III, multicenter, U.S. trial measuring seroresponse 30 days after 2 doses of MenACWY-D. Antibody titers were measured using a serum bactericidal assay containing human complement (hSBA). Seroresponse was defined as the proportion of subjects with hSBA titers of ?1:8, the accepted measure of protection. The first dose of MenACWY-D was administered alone at age 9 months, followed by a second dose administered alone (n = 404) or concomitantly with measles, mumps, rubella, and varicella vaccine (n = 302) or 7-valent pneumococcal conjugate vaccine (PCV7) (n = 422) at age 12 months. The percentage of subjects with hSBA titers ?1:8 was >90% for all meningococcal serogroups except serogroup W135 (>80%) (3).
-
Subjects:
-
Source:
-
Series:
-
ISSN:0149-2195 (print);1545-861X (digital);
-
Pubmed ID:21993344
-
Pages in Document:2 pdf pages
-
Volume:60
-
Issue:40
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
[PDF-64.63 KB]